In the ever-evolving field of healthcare, securing a spot in any medical treatment guideline is no small feat. The process requires extensive clinical research to show the medication’s safety and efficacy. We are proud to announce that Tasectan has officially been mentioned in the new guidelines of the German Society for Paediatric Gastroenterology and Nutrition (GPGN).
This means that Tasectan and Tasectan Paed are now officially mentioned on good terms in the new German guidelines for the treatment of acute infectious gastroenteritis in infants, children, and adolescents. This is a huge feather in the cap for Tasectan, demonstrating its clinically proven safety and efficacy.
Treatment guidelines are a type of clinical guideline that focuses on a specific procedure or treatment for a particular condition. The idea of clinical guidelines was designed to help improve medical care and reduce variation in treatment plans to enhance safety. These guidelines are created based on a systematic review of clinical evidence to assess the benefits of the medication or practice versus the potential harm.
Tasectan has been trusted by doctors and pharmacists for many years across several countries, thanks to the existing clinical studies and real-life patient experiences. Being included in the treatment guidelines reflects the GPGN confidence in Tasectan as a preferred treatment option for acute infectious gastroenteritis, whose benefits outweigh any potential harm.
This achievement is a huge milestone for Tasectan and Tasectan Paed. It demonstrates our commitment to providing consumers and healthcare professionals with a clinically proven and internationally trusted diarrhoea treatment.
Choose the brand trusted around the world
Find Tasectan Duo at any Clicks, Dis-Chem, or independent pharmacy or shop online.
